|
Oct 10
|
Are Medical Stocks Lagging Applied Therapeutics (APLT) This Year?
|
|
Sep 24
|
Is Applied Therapeutics (APLT) Stock Outpacing Its Medical Peers This Year?
|
|
Sep 23
|
All You Need to Know About Applied Therapeutics (APLT) Rating Upgrade to Buy
|
|
Jul 31
|
Rare Disease-Focused Applied Therapeutics' Lead Candidate Govorestat Has Blockbuster Potential, Analyst Sees 140% Stock Upside
|
|
Jun 26
|
Here's Why We're Not Too Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation
|
|
May 10
|
Applied Therapeutics Inc (APLT) Reports Q1 2024 Earnings: A Deep Dive into Financials and ...
|
|
May 9
|
Applied Therapeutics Reports First Quarter 2024 Financial Results
|
|
May 7
|
Applied Therapeutics to Present at the 2024 RBC Capital Markets Global Healthcare Conference
|
|
Apr 15
|
Applied Therapeutics Appoints Dale Hooks as Chief Commercial Officer
|
|
Apr 4
|
Applied Therapeutics to Present Results from Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at ACC 2024
|
|
Mar 28
|
UPDATE 1-US FDA extends review of Applied Therapeutics' genetic disease drug
|
|
Mar 28
|
Applied Therapeutics Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia
|
|
Mar 13
|
Applied Therapeutics (APLT) Surges 124% in a Month: Here's Why
|
|
Mar 8
|
Applied Therapeutics Inc (APLT) Announces Year-End 2023 Financial Results and Clinical Progress
|
|
Mar 6
|
Applied Therapeutics Reports Fourth Quarter and Year-end 2023 Financial Results
|
|
Feb 28
|
FDA Grants Review Date For Applied Therapeutics' First Commercial Product For Rare Metabolic Disorder
|
|
Feb 28
|
Applied Therapeutics Announces $100 Million Private Placement
|
|
Feb 28
|
Applied Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Govorestat for the Treatment of Classic Galactosemia
|
|
Feb 15
|
Applied Therapeutics Announces Positive Results from 12-month Interim Analysis of Govorestat (AT-007) in the Ongoing INSPIRE Phase 3 Trial in Sorbitol Dehydrogenase (SORD) Deficiency
|
|
Jan 4
|
Applied Therapeutics Announces Topline Results from the ARISE-HF Phase 3 Study of AT-001 in Diabetic Cardiomyopathy
|